#1
#1 out of 1
business11h ago
BioNexus Gene Lab appoints Dr. Muthu Meyyappan as Fidelion CCO to drive global VitaGuard MRD commercialization
- BioNexus Gene Lab names Dr. Muthu Meyyappan Fidelion CCO to drive global VitaGuard MRD commercialization.
- VitaGuard MRD will be marketed internationally with Southeast Asia rights held by BioNexus Gene Lab.
- Meyyappan has 15+ years in oncology diagnostics and previously held senior roles at multiple firms.
- The appointment aims to build clinical, laboratory, and pharmaceutical collaborations to promote MRD adoption.
- The news emphasizes a strategic push to grow VitaGuard MRD's global footprint.
- The report notes the content is an AI-powered summary of SEC filings and may require verification.
Vote 0